Vault Bioventures’ Post

In this week's Metabolic News Weekly, Vault Bioventures's team has curated several advancements in metabolic health including promising clinical trial results for Altimmune, Inc.'s #Pemvidutide in treating #MASLD, significant research funding for studying insulin resistance and #obesity, and new insights into the environmental impacts on metabolic syndrome, recent studies that underscore the effectiveness of high-intensity interval training (#HIIT) over moderate-intensity continuous training (#MICT) for obesity management. These developments indicate significant potential for improved treatments and preventive measures in metabolic health. Check out these stories and more 👇👇

From Endocrine Society's #Endo2024, Novo Nordisk diabetes medications and obesity treatments to recent studies and innovations that are unveiling transformative solutions for chronic diseases and metabolic disorders, this edition of Metabolic News Weekly showcases the impact of diabetes medications on cardiovascular health, novel obesity treatments, and findings that underscore the critical intersections of diet, medication, and overall health. 🔎 Key Insights: ⏵ Diabetes Medications & #Cardiovascular Health ⏵ Diet & #Diabetes Management ⏵ #Obesity & Metabolic Health ⏵ Liver Disease & Childhood Inactivity ⏵ Natural Remedies ⏵ Sexual Health & #Stress ⏵ Metabolic Syndrome & Chronic Kidney Disease (#CKD) ⏵ Genetic Discoveries 💥Impact: These revelations are set to revolutionize the approach to managing chronic diseases and metabolic disorders. The integration of advanced medications like GLP-1 receptor agonists, natural remedies, and lifestyle interventions highlights a comprehensive strategy to enhance patient outcomes. Healthcare providers and researchers can harness these insights to develop more effective, personalized treatment plans, ultimately improving the quality of life for millions. Check out this edition of Metabolic News Weekly 👇

In a recent randomised controlled #trial, #researchers found that #semaglutide (the active ingredient in medications #Wegovy and #Ozempic) significantly reduced the risk of heart attack in at-risk people with #overweight and #obesity but without #diabetes. Approximately 7.6 million people in the UK are affected by heart diseases. There are considerations now that widespread prescription of semaglutide, and other gut hormone medications, could lead to substantial cost savings for healthcare systems and economic benefit of a healthier workforce. John Deanfield CBE, Director of the National Institute for Cardiovascular Outcomes Research and co-author on the study, believes semaglutide holds similar potential to statins for improving cardiovascular health: ‘We now have a class of drugs that could equally transform many chronic diseases of ageing.' Click here to read the study 👇 https://lnkd.in/eTwh9iE6

Insulin resistance refers to the diminished response of insulin-sensitive tissues to insulin signaling. Insulin cannot exert its full biological activity, which is the facilitation of glucose entrance in cells to be utilized as the primary energy substrate. The excess glucose remains in the blood circulation, a condition named hyperglycemia, and tissues shift their metabolic pathways in response to inadequate energy uptake, underpinning disorders such as impaired adipose tissue function and obesity, inflammation, dyslipidemia, production of reactive oxidative species (ROS), atherosclerosis, endothelial dysfunction and hypertension, all of which are associated with the promotion of cardiovascular diseases (CVD). Measurable changes that predict diabetes before it develops exist and are discussed in the article below. #insulinresistance #homoir #diabetes

"A new paper surveying advances in #diabetes pathogenesis and treatment explores the complex factors contributing to the onset and progression of the disease, suggesting that an understanding of these dynamics is key to developing targeted interventions to reduce the risk of developing diabetes and managing its complications." "...some recent discoveries represent significant strides toward managing and perhaps even reversing the disease. For instance, a 2019 study found that a 14-day course of the antibody teplizumab delayed the progression of #type1diabetes from stage 1 to stage 3 by 24 months. A follow-up analysis in 2021 showed that the delay could be up to 32.5 months." Recent insights and advances in treatment and management show promise in stemming the growing prevalence of diabetes https://lnkd.in/gj87iyT4 #T1D #ScientificResearch #HCP #physicians #STOPT1D

Although people with type 2 diabetes are twice as likely to develop cardiovascular disease than those without diabetes, it remains a challenge for clinicians to predict who among this population is most at risk. An international team of researchers has identified 13 biomarkers that significantly improve the ability to accurately predict cardiovascular disease risk in people with type 2 diabetes. The analysis was published in Communications Medicine. “More than 500 million people worldwide live with diabetes. With numbers that high, it’s important to identify readily available ways to accurately classify patients so that those at higher risk of cardiovascular disease can receive the preventative care they need”, says Maria F. Gomez, co-senior author of the analysis and professor of physiology at LUDC. Read more: https://lnkd.in/dq4GQdsH Read about the story behind the paper: https://lnkd.in/diDXdAJh Johns Hopkins Medicine The Chinese University of Hong Kong Medicinska fakulteten, Lunds universitet   #diabetesresearch #diabetes #type2diabetes #t2d #cardiovasculardisease #cardiovasculardiseases

Exciting news in diabetes research: a groundbreaking study suggests psilocybin, the compound found in magic mushrooms, could protect insulin-producing cells in the pancreas. Led by Professor Igor Kovalchuk, researchers discovered psilocybin's potential in safeguarding pancreatic β-cells from stress and damage characteristic of diabetes. This promising finding opens new avenues for therapeutic approaches in combating the global rise of diabetes. While further research is needed to fully understand psilocybin's efficacy, these initial results offer hope for innovative solutions in the fight against diabetes. Together, let's push the boundaries of science and explore nature's remedies for a brighter, healthier future. #DiabetesResearch #Psilocybin #HealthInnovation

Diet and physical activity interventions to improve cardiovascular disease risk factors in liver transplant recipients: Systematic review and meta-analysis https://lnkd.in/dtPJqMbh #physiotherapy #physicaltherapy #physio #research

𝗣𝗿𝗼𝗺𝗶𝘀𝗶𝗻𝗴 𝗥𝗲𝘀𝘂𝗹𝘁𝘀 𝗳𝗼𝗿 𝗖𝗮𝘂𝘀𝗮𝗹 𝗗𝗶𝗮𝗯𝗲𝘁𝗲𝘀 𝗧𝗵𝗲𝗿𝗮𝗽𝘆   By knocking out the insulin-inhibitory receptor 𝗶𝗻𝗰𝗲𝗽𝘁𝗼𝗿, scientists at #HelmholtzMunich, Technische Universität München, Ludwig-Maximilians-Universität München and German Center for Diabetes Research (Deutsches Zentrum für Diabetesforschung, DZD) found an enhanced glucose regulation. 💡 This makes 𝗶𝗻𝗰𝗲𝗽𝘁𝗼𝗿 a prospective drug target for #type2diabetes.   𝗜𝗻 𝗗𝗲𝘁𝗮𝗶𝗹: The novel study in mice with diet-induced obesity demonstrates that global, neuronal and beta cell-specific knock-out of inceptor improves glucose control. These findings support the idea that enhancing insulin sensitivity through targeting inceptor shows promise as a pharmacological intervention, especially concerning the health and function of beta cells. 👉Learn more about these findings, led by #HelmholtzMunich experts 𝗣𝗿𝗼𝗳. 𝗛𝗲𝗶𝗸𝗼 𝗟𝗶𝗰𝗸𝗲𝗿𝘁 and Prof. Dr. Timo Müller: ➡ https://lnkd.in/dyW-B6CT   #T2D #type2diabetes #diabetes #therapy #insulin #glucose #research #Health #diabetes #inceptor #therapy

🔍📊 Excited to share our latest article entitled "Glucose-lowering drugs and liver-related outcomes among individuals with type 2 diabetes: A systematic review of longitudinal population-based studies" published in DiabeticMedicine, which is the official journal of Diabetes UK. 🔍 Key Finding: Observational data from population-based studies suggest that GLDs, especially SGLT2 inhibitors are associated with beneficial long-term liver-related outcomes in type 2 diabetes patients with NAFLD. 🍀 Understanding the connection between these medications and liver health is crucial for optimizing treatment strategies and improving patient outcomes. 🩺 A huge thank you to Dr. M Shafi Kuchay, Dr. Amirhossein Habibzadeh, and all our colleagues for their invaluable contributions to this research. 🙏 https://lnkd.in/drDngefi #NAFLDManagement #GlucoseLoweringDrugs #LiverHealth #Type2Diabetes #NAFLD #SGLT2Inhibitors #SystematicReview #DiabeticMedicine #ClinicalResearch #HealthcareAdvances #PopulationHealth #LongitudinalStudies